We have previously shown that human papillomavirus type 16 (2, 7, 12, 28, 30) . Previous studies showed that the steroid hormones progesterone and the glucocorticoid dexamethasone markedly enhanced transformation by HPV-16 in primary rodent cells in culture (23, 24) . Dexamethasone also increased immortalization of primary foreskin keratinocytes by HPV-16 and the transformation of HPV-16-immortalized keratinocytes by the activated 27) . Recently, we showed that dexamethasone and progesterone increased the episomal expression of HPV-16 genes in primary human cervical keratinocytes (18). Steroid hormones could act directly through the viral glucocorticoid/ progestin response element (GRE) sequences in the regulatory region of 8, 18) . Here, we examined this direct role of steroid hormones in the induction of HPV-16 transformation, transient expression, and in vitro DNAprotein interactions.
at nucleotides 7385 and 7474, were mutated. The previously described GRE and the other two GREs were shown to be functional for the induction of transformation by dexamethasone. In addition, transient assays in cervical HeLa cells demonstrated the functional importance of the three individual GREs. Assays for in vitro interaction demonstrated the specific binding of a 97-kDa protein, the glucocorticoid receptor, to both recently identified HPV-16 GREs.
There is increasing evidence of a causal role of human papillomaviruses (HPVs) in the pathogenesis of a number of human malignancies, especially the cervical carcinomas that cause the second highest worldwide female mortality of cancers (22, 33) . HPV type and HPV-18 are the prevalent types associated with premalignant cervical lesions and cervical carcinomas (32) . Hormones are one of the putative cofactors, as shown by a correlation of this cancer with the number of pregnancies and the level and duration of oral contraceptive usage (2, 7, 12, 28, 30) . Previous studies showed that the steroid hormones progesterone and the glucocorticoid dexamethasone markedly enhanced transformation by HPV-16 in primary rodent cells in culture (23, 24) . Dexamethasone also increased immortalization of primary foreskin keratinocytes by HPV-16 and the transformation of HPV-16-immortalized keratinocytes by the activated Ha-ras (6, 27) . Recently, we showed that dexamethasone and progesterone increased the episomal expression of HPV-16 genes in primary human cervical keratinocytes (18) . Steroid hormones could act directly through the viral glucocorticoid/ progestin response element (GRE) sequences in the regulatory region of HPV-16 (4, 8, 18) . Here, we examined this direct role of steroid hormones in the induction of HPV-16 transformation, transient expression, and in vitro DNAprotein interactions.
To study the role of HPV-16 GREs and hormones in transformation, the GREs of whole genomic HPV-16 constructs were disrupted by site-directed mutagenesis. Double and triple GRE mutation constructs were generated with one or two cycles of hybridization between different mutated plasmids. Four of the site-directed mutations have been previously described (18) , and the others were generated with analogous procedures (Table 1) . Transformation assays in baby rat kidney (BRK) cells were performed as described previously (1, 24) , with 5 ,ug of HPV-16 constructs, 5 ,ug of activated c-Ha-ras-1, and 0 or 100 nM dexamethasone. Transformation by wild-type HPV-16 was induced threefold * Corresponding author.
in the presence of dexamethasone ( Table 1 ). The loss-offunction mutation inpmHPV2 did not significantly affect the wild-type response to dexamethasone. The nucleotide (nt) 7640 consensus GRE in pmHPV4 resulted in the earlier appearance of colonies than for the wild type and a higher transforming efficiency in the absence and presence of hormone, indicating the importance of this GRE (Table 1) . Next, the functional role of the two recently identified GREs (18) in glucocorticoid induction of transformation was evaluated. The mutation of both in pmHPV56 resulted in significantly reduced transformation but only a 33% lower than wild-type level of induction with dexamethasone ( Table 1) . The mutation of all three GREs completely eliminated the wild-type hormone response observed in the transformation assays. These results indicate that dexamethasone has a direct role in vivo in the oncogenicity of HPV-16 and that the two recently identified GREs are involved.
To measure the functional role of steroid hormones in inducing gene expression from HPV-16 DNA containing all three GREs, the cervical carcinoma cell line HeLa, which is known to contain and express HPV genes (25) , was used. The wild-type construct pCPH was induced 3.5-fold in the presence of dexamethasone (Fig. 1A) . The loss-of-function mutations of each of the GREs in pCPH2, pCPH5, and pCPH6 did not significantly change the response to dexamethasone. The consensus nt 7640 GRE in pCPH4 resulted in more than 10-fold induction. Therefore, the efficiency of hormone induction of the HPV-16 wild-type GREs may be significantly less than optimum. The lower efficiency probably involves the absence of the critical C (21), which is in the consensus pmHPV4 but not in any wild-type HPV-16 GRE (Table 1 ). In addition, the loss of the overlapping AP-1 site (9, 16) might negatively regulate the nt 7640 GRE. Induction levels for the single wild-type nt 7385 and 7640 GREs in pCPH26 and pCPH56 were the same as for the three constructs with two intact GREs. However, the triple mutation completely eliminated induction. This result clearly indicated the direct effect of the HPV-16 GREs. To test the function of the recently identified GREs in the absence of other enhancer sequences, plasmids containing only single NOTES 5657 wild-type GREs were examined. Both GREs responded to dexamethasone to the same extent as whole enhancer constructs containing single wild-type GREs (Fig. 1B) . Comparison of pCPH56 and pCPH256 confirms that the wild-type nt 7640 GRE is also functional for induction in the absence of the other GREs ( Fig. 1 ; Table 1 ) (8) . Therefore, all three GREs of the HPV-16 enhancer were independently functional.
As is true for most viral enhancers, regulation of the HPV-16 enhancer function involves many different viral and cellular factors (9, 20) . This overall complexity may explain the variability of the effects of first-site GRE mutations in the context of different second-site GRE mutations. Variations are also seen between results for BRK and HeLa cells. These variations are seen more for basal than for induction levels, as expected because of the influence of many non-GRE-binding factors on basal-level expression and the influence of only the GRE-binding hormone receptor on induction. The use of the different BRK and HeLa systems allows consideration of the effect of non-GRE-binding factors. For example, the induction may be much less for pmHPV4 in BRK cells versus pCPH4 in HeLa cells because of the higher versus lower than wild-type basal levels ( Table 1 versus Fig.  1A ). The effect of this mutation on basal levels may involve the AP-1 site and the diverse cellular factor complexes that also bind to the composite site at nt 7640 (9, 16).
Another transient assay, which was used in our previous study (18) , is the nonquantitative in situ hybridization assay of HPV early-region RNA. Both transient assays could detect high levels of induction (18) (Fig. 1) . Both also use episomal DNA, and episomal DNA is also found in precancerous HPV-16-infected cervical epithelial cell lesions. A third advantage, and a distinction from the transformation Table 1 . The medium contained 5% dextran-coated, charcoal-treated fetal calf serum; transfections included 2 pg of pHGO to increase induction by GR (15) and a p-galactosidase internal control. Chloramphenicol acetyltransferase (CAT) assays were performed as described previously (10) . The single, double, and triple GRE mutation constructs were used in assays with the human cervical carcinoma cell line HeLa. Fold induction represents the induced (plus dexamethasone)/noninduced (minus dexamethasone) ratio compared with that of the pBLCAT2 control. (A) pCPH series of mutated plasmids contained the PstIHphI nt 6850 to 7889 whole enhancer fragments of the HPV-16-mutated constructs at BamHI of pBLCAT2 (17); (B) activity and induction for oligonucleotides with sequence motifs for the two recently identified GREs. Plasmids pGRE5WT and pGRE6WT were generated by using the partly double-stranded oligonucleotides Mobility shift assays with oligonucleotides for the two recently identified GREs. Mobility shift assays were performed as described previously (3), using 10 ptg of HeLa whole cell extract (31) protein, 5 p,g of poly(dI-dC), and 10,000 cpm of probe in 10 ,u. The probes were the end-labeled oligonucleotides described for Fig. 1B . Lanes: F, free probe without extract or competitor; B, binding of probe with HeLa extract; S, specific competition of binding with a 1,000-fold excess of homologous competitor; NS, nonspecific competition with a 1,000-fold excess of JC virus region II NFl-binding oligonucleotide (14) . Arrows indicate specific signals. (a) nt 7385 GRE probe; (b) nt 7474 GRE probe.
assays, is that both transient assays were in the cervical epithelial cell system. An additional advantage only for the transient assays with the HeLa/reporter gene system is that these assays are quantitative even at high levels of gene expression. The advantage of the transformation assays is that they are performed in vivo, are quantitative for lower levels of gene expression, and moreover are informative of the direct oncogenicity of HPV-16.
The glucocorticoid receptor (GR) is a cytoplasmic protein that is targeted to the nucleus only in the presence of its hormone ligand (19) , and GR may directly bind to HPV-16 GREs. Direct binding to GR is also indicated by the loss of HPV induction due to the hormone antagonist RU486 (18, 26) (5, 29) . Probes were as in Fig. 2 ; labels and conditions for electrophoresis were as in Fig. 3 .
GRE (4, 8) . Mobility shift assays were done with HeLa whole cell extracts and nt 7385 and 7474 GRE oligonucleotide probes ( Fig. 2a and b, respectively) . Both GREs gave a lower-mobility band. The significance of this binding was confirmed by using specific and nonspecific competitors. The identical mobilities for both GREs suggested that the two GREs were bound by the same protein. Selective DNA-protein interaction of the recently identified GREs was further examined by using UV cross-linking (Fig. 3) . A protein that is the size of the GR (13) and the smaller polypeptides that are the size of the GR degradation products (11) were observed with whole cell extracts from HeLa cells. The third in vitro binding assay was with Southwestern (DNA-protein) blot analysis using nuclear extracts enriched in GR by dexamethasone treatment of HeLa cells. Only the 97-kDa protein was observed. As with the other two in vitro analyses, results were consistent for the two GRE probes (Fig. 4) . The nt 7385 and 7474 GREs have unique sequences that share only the GRE-binding motif. Therefore, the data for the three different in vitro binding assays that identify proteins with identical GR-like (11) properties (Fig. 2 to 4) show that the mechanism for induction involves direct interaction of the 97-kDa native GR with the HPV-16 GREs. Furthermore, these results extend previous studies of the HPV-16 enhancer and the nt 7640 GRE (4, 8) to describe the complexity of the induction by hormone of the enhancer.
In summary, the results with the two unique in vivo assays and the three in vitro assays are consistent in their predictions of a mechanism for steroid hormone induction of HPV-16 oncogenicity and gene expression-the three individually acting HPV-16 GREs are the sole mediators, involving direct interaction with GR.
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